Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jennifer H Choe

Showing results (1-10 of 15) with videos related to

Pageof 2
Sort By:
Advanced Drug Delivery Reviews|September 4, 2021
Guiding immunotherapy combinations: Who gets what?Michelle N Ferreira, Jennifer H Choe
Seminars in Radiation Oncology|March 16, 2025
Metastatic Head and Neck Cancer: Immunotherapy and BeyondKirsten V Nguyen, Cody M Lebeck Lee, Jennifer H Choe
European Thyroid Journal|December 14, 2023
Real-world practice patterns and outcomes for RAI-refractory differentiated thyroid cancerAndrew G Gianoukakis, Jennifer H Choe, Daniel W Bowles, et al.
Journal of Vascular and Interventional Radiology : JVIR|October 11, 2022
Salvage Cryoablation for Local Recurrences of Thyroid Cancer Inseparable from the Trachea and Neurovascular StructuresAlan Alper Sag, Jennifer M Perkins, Hadiza S Kazaure, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 31, 2022
Phase Ia/b, Open-Label, Multicenter Study of AZD4635 (an Adenosine A2A Receptor Antagonist) as Monotherapy or Combined with Durvalumab, in Patients with Solid TumorsEmerson A Lim, Johanna C Bendell, Gerald S Falchook, et al.
Journal of the National Cancer Institute|December 4, 2025
Cisplatin during radiation for head and neck cancer: insights from NRG Oncology experienceLuana G Sousa, James Edward Bates, Payal Anand, et al.
The Lancet. Oncology|October 24, 2023
Neoadjuvant cemiplimab and surgery for stage II-IV cutaneous squamous-cell carcinoma: follow-up and survival outcomes of a single-arm, multicentre, phase 2 studyNeil D Gross, David M Miller, Nikhil I Khushalani, et al.
Biorxiv : the Preprint Server for Biology|November 22, 2024
Tenascin-C potentiates Wnt signaling in thyroid cancerHeather A Hartmann, Matthew A Loberg, George J Xu, et al.
The New England Journal of Medicine|September 12, 2022
Neoadjuvant Cemiplimab for Stage II to IV Cutaneous Squamous-Cell CarcinomaNeil D Gross, David M Miller, Nikhil I Khushalani, et al.
Endocrinology|February 14, 2025
Tenascin-C Potentiates Wnt Signaling in Thyroid CancerHeather A Hartmann, Matthew A Loberg, George J Xu, et al.
Pageof 2

Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
Advanced Drug Delivery Reviews|September 4, 2021
Guiding immunotherapy combinations: Who gets what?Michelle N Ferreira, Jennifer H Choe
Seminars in Radiation Oncology|March 16, 2025
Metastatic Head and Neck Cancer: Immunotherapy and BeyondKirsten V Nguyen, Cody M Lebeck Lee, Jennifer H Choe
European Thyroid Journal|December 14, 2023
Real-world practice patterns and outcomes for RAI-refractory differentiated thyroid cancerAndrew G Gianoukakis, Jennifer H Choe, Daniel W Bowles, et al.
Journal of Vascular and Interventional Radiology : JVIR|October 11, 2022
Salvage Cryoablation for Local Recurrences of Thyroid Cancer Inseparable from the Trachea and Neurovascular StructuresAlan Alper Sag, Jennifer M Perkins, Hadiza S Kazaure, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 31, 2022
Phase Ia/b, Open-Label, Multicenter Study of AZD4635 (an Adenosine A2A Receptor Antagonist) as Monotherapy or Combined with Durvalumab, in Patients with Solid TumorsEmerson A Lim, Johanna C Bendell, Gerald S Falchook, et al.
Journal of the National Cancer Institute|December 4, 2025
Cisplatin during radiation for head and neck cancer: insights from NRG Oncology experienceLuana G Sousa, James Edward Bates, Payal Anand, et al.
The Lancet. Oncology|October 24, 2023
Neoadjuvant cemiplimab and surgery for stage II-IV cutaneous squamous-cell carcinoma: follow-up and survival outcomes of a single-arm, multicentre, phase 2 studyNeil D Gross, David M Miller, Nikhil I Khushalani, et al.
Biorxiv : the Preprint Server for Biology|November 22, 2024
Tenascin-C potentiates Wnt signaling in thyroid cancerHeather A Hartmann, Matthew A Loberg, George J Xu, et al.
The New England Journal of Medicine|September 12, 2022
Neoadjuvant Cemiplimab for Stage II to IV Cutaneous Squamous-Cell CarcinomaNeil D Gross, David M Miller, Nikhil I Khushalani, et al.
Endocrinology|February 14, 2025
Tenascin-C Potentiates Wnt Signaling in Thyroid CancerHeather A Hartmann, Matthew A Loberg, George J Xu, et al.
Pageof 2